Our data show for the first time that increasing miR-342-5p intrinsically reduces imatinib resistance in CMLMiR-342-5p acts as a tumor suppressor in CML by suppressing the expression of BCR-ABL and CCND1 (Figs. 2 and 3). Here, CCND1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.